{"id":"nmra-335140","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug targets the 5-HT7 receptor, a serotonin receptor subtype implicated in mood regulation, circadian rhythm control, and emotional processing. By antagonizing this receptor, NMRA-335140 aims to provide therapeutic benefits in psychiatric and neurological conditions. This mechanism represents a novel approach to treating mood disorders through a less commonly targeted serotonergic pathway.","oneSentence":"NMRA-335140 is a selective serotonin 5-HT7 receptor antagonist designed to modulate mood and emotional processing through central nervous system effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:23:13.175Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"}]},"trialDetails":[{"nctId":"NCT06058013","phase":"PHASE3","title":"Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder","status":"RECRUITING","sponsor":"Neumora Therapeutics, Inc.","startDate":"2023-12-20","conditions":"Major Depressive Disorder","enrollment":332},{"nctId":"NCT06029439","phase":"PHASE3","title":"Study to Assess the Safety and Effectiveness of NMRA-335140-501","status":"RECRUITING","sponsor":"Neumora Therapeutics, Inc.","startDate":"2023-11-10","conditions":"Major Depressive Disorder","enrollment":1000},{"nctId":"NCT06058039","phase":"PHASE3","title":"Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder","status":"RECRUITING","sponsor":"Neumora Therapeutics, Inc.","startDate":"2023-12-21","conditions":"Major Depressive Disorder","enrollment":332},{"nctId":"NCT06029426","phase":"PHASE3","title":"Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder","status":"COMPLETED","sponsor":"Neumora Therapeutics, Inc.","startDate":"2023-09-20","conditions":"Major Depressive Disorder","enrollment":383},{"nctId":"NCT06429722","phase":"PHASE2","title":"To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.","status":"COMPLETED","sponsor":"Neumora Therapeutics, Inc.","startDate":"2024-05-13","conditions":"Major Depressive Episode Associated With Bipolar II Disorder","enrollment":18},{"nctId":"NCT04221230","phase":"PHASE2","title":"Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo","status":"COMPLETED","sponsor":"Neumora Therapeutics, Inc.","startDate":"2020-01-03","conditions":"Major Depressive Disorder","enrollment":204}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BTRX 335140","CYM-53093","Navacaprant","BTRX-335140"],"phase":"phase_3","status":"active","brandName":"NMRA-335140","genericName":"NMRA-335140","companyName":"Neumora Therapeutics, Inc.","companyId":"neumora-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NMRA-335140 is a selective serotonin 5-HT7 receptor antagonist designed to modulate mood and emotional processing through central nervous system effects. Used for Major depressive disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}